[ORGANIZATION]
Amgen Inc.
Featured in 8 tracked stories · first seen
Situations
Sjögren disease research and drug development
2 clusters · 5 sources · last updated
Latest: Amgen reports positive Phase 3 trial results for Sjögren’s drug
Recent clinical developments regarding Sjögren disease, a chronic autoimmune disorder, have focused on both long-term patient risks and new therapeutic options. Research presented at the American College of Rheumatology
Also covered in
-
Analysts raise Amgen target to $440 and cut American Electric Power target to $142
[BUSINESS] · 2 sources ·